van Mulligen E, et al. - In this multicentre single-blinded (research nurses) randomized controlled trial, authors investigated the efficiency of 2 tapering strategies following the achievement of controlled disease in subjects with rheumatoid arthritis (RA), during 1 year of follow-up. Ninety-five candidates were randomly assigned to tapering anti-TNF vs 94 subjects to tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD). They observed 33% and 43% of the respective cumulative flare rates in the csDMARD and anti-TNF tapering group. No difference was reported in mean Disease Activity Score (DAS), Health Assessment Questionnaire Disability Index (HAQ-DI) and EQ-5D between tapering groups after 1 year and over time. They suggested tapering TNF inhibitor first due to possible cost reductions and less long-term side effects.